CMA1 and diabetic kidney disease: In diabetic nephropathy rodent models, chymase inhibition protected diabetic rats from renal lesions [23], and chymase released TGF-β1 from the extracellular matrix (ECM) via specific proteolytic cleavage of the latent TGF-β binding protein to increase cellular inflammation [24].